Enhancement of endothelial progenitor cell numbers and migration by H1152, a Rho kinase specific inhibitor.
Endothelial progenitor cells (EPCs) are applied in the treatment of ischemic diseases. In ex vivo culture of human cord-blood derived EPCs, H1152, (S)-(+)-2-methyl-1-[(4-methyl-5-iso-quinolinyl) sulfonyl]-homopiperazine, markedly increased the number of EPCs. It also induced EPC migration, stimulated the phosphorylation of AKT, and reduced the expression of p27 in the EPCs. Thus H1152 can be used effectively in ex vivo expansion of EPCs.
Cancer Research Institute and Department of Medical Lifescience, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Eunju
E
O
Seung Woo
SW
Lee
Hyun-Sun
HS
Lee
Hee-Suk
HS
Lim
Hyun-Young
HY
Ahn
Jong-Chul
JC
Shin
Yonggoo
Y
Kim
Young Ae
YA
Joe
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000031:analogs & derivatives* / Q000494:pharmacology; D002452:Cell Count; D002465:Cell Movement / Q000187:drug effects*; D042783:Endothelial Cells / Q000166:cytology*; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D013234:Stem Cells / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors*
C459092:2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine; D047428:Protein Kinase Inhibitors; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D054460:rho-Associated Kinases